Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7514355 | 1.00 | BCHE (0.33) | BCHEEZH2HTR2CSLC6A4 | |
| SCHEMBL1388984 | 1.00 | BCHE (0.33) | BCHEEZH2HTR2CSLC6A4 | |
| SCHEMBL1717405 | 1.00 | BCHE (0.33) | BCHEEZH2HTR2CSLC6A4 | |
| SCHEMBL1389062 | 1.00 | BCHE (0.33) | BCHEEZH2HTR2CSLC6A4 | |
| Hydrochloric Acid SCHEMBL7513256 | 0.99 | BCHE (0.33) | BCHEEZH2HTR2CSLC6A4 | |
| Hydrochloric Acid SCHEMBL7513262 | 0.99 | BCHE (0.33) | BCHEEZH2HTR2CSLC6A4 | |
| SCHEMBL7525880 | 0.99 | BCHE (0.32) | BCHEEZH2 | |
| SCHEMBL7525881 | 0.99 | BCHE (0.32) | BCHEEZH2 | |
| SCHEMBL7526413 | 0.96 | PTGER1 (0.31) | — | |
| SCHEMBL7526409 | 0.96 | PTGER1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | ICOS, CD14, MAVS | BCHE 1608/4885EZH2 2730/4885HTR2C 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.